Gilead-Teva Patent Deal Cost Drug Buyers Over $2B, Jury Told
By Bonnie Eslinger · June 13, 2023, 10:23 PM EDT
A retired Harvard Medical School health economics professor testified Tuesday in a California federal antitrust trial over claims that Gilead and Teva struck an illegal "pay for delay" patent deal over...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login